Methyl 3-Cyclopropyl-3-Oxopropionate Bulk Price 2026: Manufacturer Direct Analysis
- R&D Focus: Optimized synthesis routes ensuring ≥98.5% purity for pitavastatin intermediates.
- Procurement Focus: Stable tonnage supply with verified COA and factory-direct pricing models.
- Executive Focus: Full regulatory compliance support and scalable production capacity for 2026 demand.
Methyl 3-Cyclopropyl-3-Oxopropionate (CAS: 32249-35-7) serves as a critical organic building block in the pharmaceutical industry, specifically within the synthesis of pitavastatin, a potent HMG-CoA reductase inhibitor. As global demand for cholesterol management therapies evolves, securing a reliable supply chain for this key intermediate is paramount for contract development and manufacturing organizations (CDMOs). This analysis provides a comprehensive overview of the bulk price projections for 2026, technical specifications, and procurement strategies tailored for industrial-scale operations.
Market Price Trends for CAS 32249-35-7
Forecasting the cost landscape for specialized keto esters requires an understanding of raw material volatility and production complexity. While small-scale laboratory reagents often command premium pricing due to packaging and handling overheads, industrial procurement operates on a different economic model. Market data indicates that unit costs decrease significantly as order volumes transition from gram-scale to kilogram and tonnage quantities.
For 2026, pricing stability is expected to hinge on the availability of cyclopropane derivatives and methyl ester precursors. A global manufacturer with integrated supply chains can mitigate these fluctuations better than distributors relying on spot markets. Buyers should anticipate that factory-direct engagements will offer the most competitive rates, bypassing multiple layers of distribution markup. Furthermore, establishing long-term contracts can lock in favorable rates, protecting projects from sudden spikes in chemical commodity prices.
Technical Specifications and Synthesis Route Optimization
From a process chemistry perspective, the quality of the intermediate directly impacts the yield and purity of the final active pharmaceutical ingredient (API). Standard market offerings often hover around 96% purity, which may necessitate additional downstream purification steps. However, advanced manufacturing processes can achieve higher industrial purity levels, reducing waste and improving overall process efficiency.
The preferred synthesis route involves the cyclopropanation of appropriate acrylic acid derivatives followed by esterification. Controlling impurity profiles, such as residual solvents or unreacted starting materials, is critical for regulatory approval. At NINGBO INNO PHARMCHEM CO.,LTD., production protocols are designed to minimize side reactions, ensuring batch-to-batch consistency that meets stringent pharmaceutical standards.
| Parameter | Specification | Test Method |
|---|---|---|
| Chemical Name | Methyl 3-Cyclopropyl-3-Oxopropionate | - |
| CAS Number | 32249-35-7 | - |
| Molecular Formula | C7H10O3 | - |
| Formula Weight | 142.15 g/mol | - |
| Purity (GC) | ≥ 98.5% | Gas Chromatography |
| Appearance | Colorless to Light Yellow Liquid | Visual |
| Boiling Point | ~80°C (under reduced pressure) | Distillation |
| Packaging | 25kg / 200kg Drums | - |
Volume Discount Structures for Global Manufacturer
Procurement strategies for chemical intermediates must account for total cost of ownership, which includes logistics, quality assurance, and supply security. Volume discount structures are typically tiered based on annual commitment or single-order quantity. For high-volume users, negotiating directly with the production facility allows for customized packaging solutions and dedicated inventory allocation.
When sourcing high-purity Methyl 3-Cyclopropyl-3-Oxopropanoate, buyers should verify that the supplier can provide comprehensive documentation. This includes a detailed Certificate of Analysis (COA) for every batch, Safety Data Sheets (SDS), and regulatory support files. NINGBO INNO PHARMCHEM CO.,LTD. emphasizes transparency in quality control, ensuring that all shipped materials meet the specified technical agreements before leaving the facility.
Requesting a Quote for Bulk Procurement
Securing supply for 2026 and beyond requires proactive engagement with manufacturing partners. Executives and procurement officers should prioritize suppliers who demonstrate regulatory compliance capabilities, such as support for REACH or TSCA inquiries, alongside robust production capacity. It is essential to confirm that the supplier adheres to strict shipping protocols, ensuring materials are handled by technically qualified personnel and delivered safely to industrial facilities.
To initiate the procurement process or discuss custom synthesis requirements, we encourage you to contact our technical sales team for a batch-specific COA, SDS, or bulk pricing quote. Partnering with a dedicated manufacturer ensures that your production timelines are met with the highest standards of quality and reliability.